A recent study has highlighted the risks and benefits associated with the administration of intermittent androgen deprivation therapy in patients with metastatic prostate cancer. Although there are improvements in many quality-of-life domains, these improvements must be carefully weighed against the potential harms of intermittent androgen deprivation therapy in this patient population.
Key Points
The decision to administer intermittent or continuous androgen deprivation therapy to patients with metastatic prostate cancer must be individualized to reflect patients' preferences surrounding various quality-of-life domains.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Alibhai, S. M. et al. Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J. Clin. Oncol. 28, 5038–5045 (2010).
Sadetsky, N. et al. Impact of androgen deprivation on physical well-being in patients with prostate cancer: analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry. Cancer 117, 4406–4413 (2011).
Hussain, M. et al. Intermittent versus continuous androgen deprivation in prostate cancer. N. Engl. J. Med. 368, 1314–1325 (2013).
Crook, J. M. et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N. Engl. J. Med. 367, 895–903 (2012).
Calais da Silva, F. E. et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur. Urol. 55, 1269–1277 (2009).
Jaeschke, R., Singer, J. & Guyatt, G. H. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin. Trials 10, 407–415 (1989).
Juniper, E. F., Guyatt, G. H., Willan, A. & Griffith, L. E. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J. Clin. Epidemiol. 47, 81–87 (1994).
Wells, G. A. et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J. Rheumatol. 20, 557–560 (1993).
Norman, G. R., Sloan, J. A. & Wyrwich, K. W. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med. Care 41, 582–592 (2003).
Acknowledgements
The author acknowledges support from the Veterans Affairs National Quality Scholars Program and the T. J. Martell Foundation, and the use of facilities at Veterans Health Administration Tennessee Valley Healthcare System.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author is a Consultant and Advisor for Dendreon Corporation.
Rights and permissions
About this article
Cite this article
Resnick, M. Walking the tightrope of survival and quality of life with ADT. Nat Rev Clin Oncol 10, 307–308 (2013). https://doi.org/10.1038/nrclinonc.2013.78
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2013.78
This article is cited by
-
A Time Scales Approach for Modeling Intermittent Hormone Therapy for Prostate Cancer
Bulletin of Mathematical Biology (2020)
